Cases & Deals

Strides Arcolab completes $1.6 billion sale of subsidiary to Mylan

Clients Strides Arcolab Limited

Jones Day advised India-based pharmaceutical company Strides Arcolab Limited ("Strides") on the antitrust aspects of the sale to Mylan Inc. of its Agila Specialties Global Pte. Ltd. ("Agila") subsidiary for $1.6 billion in cash. The deal was announced in a company press release on February 28, 2013.

Headquartered in Bangalore, India, Agila is a developer, manufacturer, and marketer of high-quality generic injectable products. Agila had the highest number of FDA approved generic injectables from 2008 to 2010. The deal is expected to expand Mylan’s global footprint and increase its injectable portfolio to approximately 700 drugs.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.